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Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent
stem cells, provide a powerful platform for mechanistic studies of disorders of neuro-
development and neural networks. hPSC models of autism, epilepsy, and other neuro-
logical disorders are also advancing the path toward designing and testing precision
therapies. The field is evolving rapidly with the addition of genome-editing
approaches, expanding protocols for the two-dimensional (2D) differentiation of dif-
ferent neuronal subtypes, and three-dimensional (3D) human brain organoid cultures.
However, the application of these techniques to study complex neurological disorders,
including the epilepsies, remains a challenge. Here, we review previous work using
both 2D and 3D hPSC models of genetic epilepsies, as well as recent advances in the
field. We also describe new strategies for applying these technologies to disease
modeling of genetic epilepsies, and discuss current challenges and future directions.
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1 | INTRODUCTION
Epilepsy is one of the most common neurological disorders
with a prevalence in the U.S. of 1.2%.1 The hallmark feature
of epilepsy is spontaneous recurrent seizures, but the disease
encompasses a wide range of etiologies, behavioral manifes-
tations, electrographic signatures, pharmacological profiles,
and histopathologies.2 Epilepsy also has a high incidence
early in life and is associated with increased mortality.
Approximately 30%-40% of patients cannot be adequately
controlled with anti-epileptic drugs.3 Only a small portion of
medically refractory patients are surgical candidates, but
most of these candidates never receive an evaluation for
resective brain surgery. Unfortunately, no therapies exist for
preventing epilepsy that may occur from various causes,
such as after head trauma, stroke, or other neurological
insult, from a genetic predisposition, or a malformation of
brain development. Overall, epilepsy poses a huge burden to
patients and their families.
The number of genes associated with epilepsy has
exploded since the first gene linked to a clinical seizure phe-
notype was discovered nearly three decades ago.4 To date,
over 500 loci are linked to epilepsy,5 but our understanding
of how these mutations lead to spontaneous seizures and
other epilepsy manifestations lags behind gene discovery.
Traditional strategies to model genetic epilepsies have
involved the use of rodent models, obtained through either
genetic modification or finding spontaneous mutations
within rodent colonies. Despite many advances made study-
ing animals, these models do not fully recapitulate human
disease phenotypes and mechanisms, likely because human
brain development differs considerably from that of the
rodent brain in many critical aspects.6-8 In addition, many
genetically modified mouse models of epilepsy fail to show
spontaneous recurrent seizures (the hallmark of epilepsy)
and may only exhibit signs of cortical network excitability
through testing of seizure thresholds after chemoconvulsant
administration. Limited scalability of rodent models also
constrains the possibility of performing rapid mutation-
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specific mechanistic studies and drug screening. Postmortem
tissues or surgical specimens from patients are difficult to
acquire and those available generally represent late-stage
disease, offering limited insight into causative mechanisms.
Zebrafish models of genetic epilepsies are gaining traction
and are extremely amenable to high-throughput drug screen-
ing.9 The fish models have only been useful for interrogating
loss-of-function epilepsy genes, although recent advances in
gene editing technologies may allow for epilepsy missense
mutations to be interrogated in zebrafish models in the
future.10 Consequently, decades of research have not pro-
duced profound mechanistic insights into any of the many
epilepsy syndromes, including the monogenic epilepsies.
The derivation of human embryonic stem cells (hESCs)
from blastocysts by the Thomson laboratory in 199811 and
the generation of mouse induced pluripotent stem cells
(iPSCs) through somatic-cell reprogramming by Yamanaka
and colleagues in 200612 opened the door for translational
research using stem cells in disease modeling and therapeu-
tic development. The discovery of mouse iPSCs was quickly
followed by the generation of human iPSCs.13,14 Soon after,
iPSC disease modeling was developed by differentiating the
cells into tissues relevant for investigating specific dis-
eases.15,16 Patient iPSCs carry the identical mutation(s) in
the context of the patient's specific genetic background.
Given the inability to acquire disease tissue for in vitro study
from a human subject with a central nervous system (CNS)
disorder during the subject's life, the differentiation of
hPSCs to neural cells or brain-like structures offers an
unprecedented opportunity to model human brain develop-
ment and brain disorders.
Various protocols have been developed to differentiate
hPSCs to neural cells that are most relevant to models of epi-
lepsy, such as cortical-like excitatory neurons,17,18 cortical-like
inhibitory neurons,19-21 dentate granule cell-like neurons22 and
astrocytes.23 These neurons in 2D cultures form functional syn-
apses and eventually neuronal networks. To better recapitulate
the architecture of the developing human brain, efforts have been
made to generate 3D cerebral organoids from iPSCs.24,25 Some
of these brain organoids have features that resemble cerebral cor-
tex, ventral telencephalon and also hippocampal anlage.25,26
More recent advances include the development of more uniform
and defined brain region-specific organoids/spheroids.27-32 Pro-
gress in neural differentiation protocols also makes iPSCs very
appealing for stem cell-based transplantation therapies for neuro-
logical disorders, an area that is being actively studied.33-37 The
application of genome editing to hPSCs further enhances the
utility of in vitro human cell models of epilepsy. Genome editing
technologies, such as TALEN (transcription activator-like effec-
tor nuclease) and CRISPR/Cas9 (clustered regularly interspaced
short palindromic repeats/CRISPR-associated protein 9 nuclease)
systems can be used to modify hPSCs directly,38,39 or
simultaneously with fibroblast reprogramming.40,41 This
approach is particularly useful given the limited access to sub-
jects with rare epilepsy mutations, or to study the effects of spe-
cific mutations in an isogenic control background.
To date, iPSCs have been generated for well over two dozen
different CNS disorders42,43 and the number continues to grow
rapidly. hPSCs have been used to model a wide array of neuro-
logical disorders with nearly completely penetrant epilepsy
phenotypes, such as Dravet syndrome (DS),44,45 Angelman syn-
drome (AS),46 variant Rett syndrome caused by cyclin-dependent
kinase-like 5 (CDKL5) mutations,47,48 and syntaxin-binding pro-
tein 1 (STXBP1)-related epileptic encephalopathy.49,50 This
approach has also been employed to model other neu-
rodevelopmental disorders with seizures as one of the com-
orbidities, including tuberous sclerosis complex (TSC),51-55
typical Rett syndrome,56-60 fragile × syndrome,61-63 Timothy
syndrome,64,65 15q11.2 deletion syndrome,66 Phelan-McDermid
syndrome,67 and Miller-Dieker syndrome.68 More recently,
hPSC cultures have been used to study microcephaly resulting
from ZIKV exposure.69 Although whole animal models still
remain critical for studying various behavioral and electrophysio-
logical features of human epilepsies, “epilepsy in a dish” models
are becoming critical platforms to study disease mechanisms and
to develop patient-specific therapeutic interventions.70,71 Below
we review recent advances in hPSC technology (with a focus on
genome editing) and iPSC-derived 2D and 3D neural culture
methods, as well as their applications for disease modeling.
Finally, we discuss the challenges and potential future directions
of these model systems.
2 | GENERATION AND GENE
EDITING OF IPSCs
The generation of patient-specific iPSC lines enables a wide
repertoire of genetic epilepsies to be modeled in culture.
iPSCs are generated by the forced expression of specific
transcription factors in somatic cells,12 a process called
“reprogramming,” to reset the epigenetic state of the cells
similar to the pluripotent state of hESCs derived from pre-
implantation human embryos. Most often, the repro-
gramming is performed on dermal fibroblasts isolated from a
skin biopsy,72 but more recently hematopoietic cells73,74 or
kidney epithelial cells derived from urine75,76 have been
used. iPSCs can self-renew and have the potential to gener-
ate cells in the three germinal lineages and their subsequent
progeny. Therefore, they provide a potentially unlimited
source of starting material from which they can be differenti-
ated into various cell types for disease modeling, drug
screening, toxicity studies, or regenerative therapies.
The utility of iPSCs can be further expanded by genome
editing, particularly using the CRISPR/Cas9 system, which can
make precise changes in cellular genomic DNA77-80 or can be
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used to modulate gene expression.81 This two-component sys-
tem consists of a Cas9 nuclease and a single guide RNA
(sgRNA) that mediates DNA binding specificity. In brief, Cas9
nuclease is targeted to a genomic DNA sequence of interest
where it introduces a double-strand break (DSB). The DSB
triggers the endogenous DNA repair machinery to repair the
break via one of two pathways: an error-prone nonhomologous
end-joining (NHEJ) pathway or a homology directed repair
(HDR) pathway.82 The NHEJ pathway joins DNA ends in a
manner that often introduces random insertion or deletion
(indel) mutations.83 These indels can introduce frame shifts and
premature stop codons when targeted to open reading frames,
thus disrupting gene function through nonsense-mediated
mRNA decay (NMD) mechanisms.84 Alternatively, when the
HDR pathway is activated in the presence of a donor template
with sequence homology to the region flanking the DSB,85 the
breaks can be repaired seamlessly with insertion of the donor
nucleotides. Changes of either single nucleotide or large exoge-
nous DNA sequences can be introduced into the genomic
region of interest when it is included in the repair template.
Using CRISPR/Cas9 genome editing, any gene of inter-
est, in theory, can be deleted or altered to interrogate its role
in biological processes, while circumventing difficulties in
obtaining patient tissues and allowing for comparison with
an isogenic control.86 Loss of function (LOF) “virtual
patient” lines can be generated through the NHEJ pathway.
Patient-specific mutations, including inherited or de novo
germline mutations, can also be edited into a control iPSC
line through HDR-mediated repair when a template carrying
the mutation is provided. Generating additional “virtual
patient” lines from the same genetic background also allows
for direct comparisons among specific patient mutations.38
However, HDR-mediated repair is less efficient than NHEJ.
The repair efficiency can vary by an order of magnitude
among cells of different types or even those of the same type
but of different genetic backgrounds.87 Moreover, a potential
limitation of using “virtual patient” lines in a control iPSC
line is the loss of patient-specific genetic modifiers. There-
fore, combining this approach with patient-specific material
is often ideal for confirming cellular phenotypes associated
with specific mutations. Alternatively, CRISPR/Cas9 based
genome editing may be used to reverse a genetic variant of
interest to the wild-type status.88 Since genotypic variability
is a major driver of phenotypic variability, isogenic controls
are vital to determine causality between genotype and phe-
notype. Such isogenic models enable subtle phenotypes to
be examined, which might not be possible when comparing
cells derived from two different individuals.89 This approach
is becoming a standard practice in the field.
Another powerful application of CRISPR/Cas9 technology
is the introduction of exogenous sequences into a specific
genomic locus via the HDR pathway to serve as a reporter for
the activity of that gene.90 When this approach is used to fuse
a fluorescent protein sequence or an epitope sequence to an
endogenous open reading frame (also called endogenous/in
frame tagging), the subcellular localization, and dynamics of
the encoded fusion protein can be analyzed under endogenous
physiological conditions.91 In addition, the knock-in of
reporter genes to label specific cell populations enables pheno-
typic analyses to be carried out in the cell types of interest.92,93
In particular, the insertion of reporter genes into developmen-
tally important loci such as FEZF2,94 OLIG2,95 or NKX2.196
has facilitated the identification and characterization of target
neuronal cell types that can be used for disease modeling or
transplantation. However, inserting a large sequence requires
HDR with a correspondingly large, exogenously provided
repair template, an inefficient process in human cells. Never-
theless, endogenous tagging offers a major improvement over
conventional overexpression systems or bacterial artificial
chromosome (BAC) approaches,97 especially for live imag-
ing91 and functional studies.98,99 The ability to endogenously
tag proteins allows analysis of the biochemical activity of
epilepsy-related proteins for which there are no validated anti-
bodies. Combined with phenotypic analysis in patient iPSC
models, this approach provides a key molecular tool to deter-
mine underlying cellular mechanisms.
Despite the rapid evolution of genome editing, the approach
still has multiple technical challenges that prevent efficient
genome editing in established iPSCs.100 First, unwanted off-
target mutations may occur. Although recent whole-genome
sequencing results show that off target editing by CRISPR/Cas9
is very low in human stem cells,101-103 this problem has been fur-
ther reduced through additional strategies such as designing
sgRNAs with very high specificity scores, using a modified
Cas9 nuclease with improved binding specificity to sgRNAs,
testing sgRNAs with different lengths and PAM sequences, and
the delivery of purified gRNA and Cas9 protein as a
CAS9-ribonucleoprotein (RNP) complex. Second, a clonal line
with homogeneous genetic background is difficult to obtain from
established iPSCs that do not recover well from single-cell clonal
isolation processes.104 The addition of a rho-associated coiled-
coil kinase (ROCK) inhibitor,104 commercially available supple-
ments for single cell isolation, or physiologic oxygen (2%) cul-
ture conditions105 have been reported to enhance clone recovery
during this harsh selection process. Some of these treatments
also likely reduce the development/accumulation of spontaneous
chromosomal aberrations over prolonged time in culture.105
An alternative strategy to overcome the obstacle of mak-
ing clonal genome-edited iPSC lines is to perform simulta-
neous reprogramming and CRISPR/Ca9 gene editing from
somatic tissues. This approach avoids multiple rounds of
clonal picking, which enables the generation of multiple
edited and unedited iPSC lines simultaneously. It also
requires considerably less time and resources compared to
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conventional multistep protocols that can take at least sev-
eral months to complete.40,41 However, this approach is
much more suitable for gene knockout than for HDR-based
mutational insertion/correction, which is the less efficient of
the two processes. Third, the efficiency of seamless genome
editing of specific mutations or correction of patient muta-
tions through HDR in the absence of selectable markers is
very low. It can be painstakingly difficult to isolate an edited
clonal line, which often makes it time- and cost-prohibitive.
However, several factors may be used to improve the pro-
cess. One is the delivery of purified gRNA and Cas9 protein
as CAS9-ribonucleoprotein (RNP) complex to avoid the
inconsistency of in vivo protein transcription and translation.
This approach improves the efficiency of genome editing in
human stem cells78,106,107 and reduces off-target mutations
associated with plasmid transfection and indels in the allele
that does not need to be modified given the reduced tempo-
ral availability of the Cas9 protein.106 Chemically or struc-
turally modified sgRNAs that bind to Cas9 nuclease more
tightly and are less prone to degradation may also signifi-
cantly enhance the efficiency of CRISPR/Cas9 mediated
genome editing.108,109 Lastly, compounds that either inhibit
the NHEJ pathway (ie, SCR7 and RS-1) or enhance HDR
efficiency (ie, L755507, brefeldin A, E1B55K and E4orf6)
can improve the efficiency of mutational insertion/correction
in human stem cells, although the in vitro toxicity of these
small molecules and proteins still requires extensive evalua-
tion (recently reviewed in Reference 100).
More recently, hPSC lines with stable or inducible expres-
sion of Cas9 protein through lentiviral integration have been
developed that allow genome-wide screening. The screening is
done by delivering thousands of gRNAs (several gRNA librar-
ies are available) into stem cells with high efficiency.110,111
For human use, it will be essential to reduce CRISPR off-
target effects, improve editing efficiency, and exploit novel
delivery strategies at a low cost and with high safety (not fur-
ther discussed here). Nevertheless, the CRISPR/Cas9 based
genome-editing system has become a powerful platform for
helping investigators determine how a specific mutation affects
cellular function and for generating high-throughput platforms
for drug screening in a dish.
3 | TWO-DIMENSIONAL NEURAL
DIFFERENTIATION
Differentiating hPSCs into disease-relevant neural cell types
offers great potential for studying the development and progres-
sion of neurological disorders. One of the goals of such studies
involving genetic epilepsies is to generate cortical networks
in vitro that closely resemble those found in vivo. Various proto-
cols have been developed to derive neural cells from hPSCs that
are most relevant to epilepsy, including cortical-like excitatory
neurons,17,18 cortical-like inhibitory neurons (γ-aminobutyric
acid [GABA]-expressing interneurons),19-21 and hippocampal-
like neurons.22,112 Recent developments in optimizing the proto-
cols of neural differentiation also make it possible to generate
astrocytes,113-115 midbrain dopamine neurons116,117 and spinal
motor neurons118,119 from hPSCs. Most of these protocols
involve the application of small molecules to hPSC monolayers
or the forced expression of specific transcription factors. Small
molecule differentiation can recapitulate some in vivo neu-
rodevelopmental processes such as inducing ventricular zone
(VZ)-like structures and transcriptional signatures. However, the
resulting neural cultures are often heterogeneous and vary
between cell lines.120 Compared to small molecule differentia-
tion, induced differentiation using transcription factors allows
rapid generation of more homogeneous cultures that exhibit
reproducible neuronal properties (2 weeks vs 4-6 weeks for small
molecule differentiation).121 However, the induced differentiation
approach bypasses normal signaling pathways during neural
development such that some developmental phenotypes in hPSC
models of neurodevelopmental disorders may be difficult to inter-
pret or completely absent.122 Below, we focus on the differentia-
tion of forebrain cortical-like excitatory and inhibitory neurons
that are relevant to the epilepsies.
3.1 | Small molecule differentiation
Based upon knowledge of the molecular cues underlying
embryonic brain development, various protocols have been
developed to direct hPSCs toward specific neuronal cell line-
ages. To differentiate iPSCs into forebrain neurons, one of
two categories of protocols is typically used: dual inhibition
of the SMAD signaling pathways (BMP and TGF-β) in
a monolayer culture,17,20,123,124 or embryoid body (EB) dif-
ferentiation.19,125-129 SMAD signaling is inhibited with pro-
teins such as Noggin and Dickkopf-1, or small molecule
inhibitors, such as SB-431542, LDN193189, and dors-
omorphin, to promote the differentiation of PSCs into a fore-
brain neural lineage. In the monolayer protocols, iPSCs are
plated as an adherent monolayer followed by rapid induction
of a neuroepithelial sheet through dual inhibition of the
SMAD signaling pathways (Noggin and SB-431542 used
in Reference 17, SB-431542 and dorsomorphin used in
Reference 124, SB-431542 and LDN193189 used in Ref-
erence 123). In EB protocols, hPSCs are allowed to form
aggregates in suspension in the absence of exogenous
growth factors or small molecules. EBs are then plated
onto an adherence-promoting substrate and cultured with
dual SMAD inhibitors, promoting formation of definitive
neuroectoderm.126,128,129 Alternatively, the EB method has
been modified by the direct application of dual SMAD
inhibitors into hPSC aggregate culture, and then cell
aggregates are plated as adherent cultures.125,127 After
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definitive neuroectoderm develops and organizes into neu-
ral rosette-like structures, the neural rosettes are selected
for continued growth and differentiation. Following the
rosette selection, cortical development of the monolayer
cultures is coupled with sequential expression of markers
for the appropriate cortical laminar projection neurons.
Compared to the monolayer protocol, EB aggregate proto-
cols generate a higher yield and purity of neurons,130 and also
result in slightly more mature neurons with longer neurites.120
Notably, electrophysiological analysis did not reveal signifi-
cant differences between these two differentiation protocols
and indicated that human neurons cultured in vitro require pro-
longed culture durations to reach synaptic maturity.120 Most
protocols generate functional but still immature cortical neu-
rons after ~4-6 weeks from the start of the differentiation. One
recent report showed that early-born cortical neurons with
functional electrophysiological properties could be generated
within 8-16 days with combinatorial application of six path-
way inhibitors,123 although this has not yet been replicated.
Variations among the differentiation protocols can result in a
bias toward development of either excitatory or inhibitory neu-
rons, depending upon modulation of the sonic hedgehog
(SHH) pathway after the development of a primitive neuro-
epithelium. For example, one can generate GABAergic inter-
neurons by patterning the neuroepithelium into a homogenous
population of NKX2.1-expressing MGE-like progenitors in
about 6 weeks using SHH and/or the smoothened activator
purmorphamine to activate the SHH pathway.19,20
3.2 | Transcription factor induced
differentiation
Compared to the small molecule differentiation method, a
quicker way to generate neurons from hPSCs is to force the
expression of lineage-determining transcription factors. We
refer here to these transcription factor-induced neurons as
iNeurons. The induced expression of Neurogenin-2 (NGN2),
for example, allows one to generate functional excitatory neu-
rons within 2 weeks.121 Analysis of these neurons shows an
overall similar transcriptional expression profile except for
lower expression of deep-layer neuronal markers, such as
TBR1,131 compared to that of those derived from EBs. These
NGN2-induced neurons display short-term plasticity, synaptic
function and modulation, and the ability to functionally inte-
grate when transplanted into the mouse brain.121,131 Transient
expression of a combination of the transcription factors
ASCL1 and DLX2, or these two factors plus LHX6 and a spe-
cific microRNA generates functional GABAergic interneurons
from hPSCs with a high degree of synaptic maturation.132,133
These inhibitory iNeurons consist of various populations of
GABAergic neurons that express subtype-specific markers
and display inhibitory synaptic function. They can also
integrate into host synaptic circuits after grafting in vivo.132
When co-cultured with NGN-2 excitatory iNeurons, the gener-
ation of these defined populations of functionally mature
human GABAergic iNeurons provides a new platform for the
study of diseases affecting inhibitory synaptic transmission A
remaining challenge is that none of the current protocols reli-
ably generates parvalbumin-expressing fast-spiking interneu-
rons, a cell type critical for many epilepsies and other
neurological and psychiatric disorders.
4 | THREE-DIMENSIONAL HUMAN
BRAIN ORGANOID MODELS
The human brain is one of the most complex organs in the
animal kingdom, and has more types of neurons and
regional diversity than that of other mammals.6,134 One criti-
cal aspect of human brain development is the generation of
an outer subventricular zone (oSVZ), which contains a large
population of outer radial glia (oRG; also known as basal
RG—bRG) progenitor cells. oRG are present in large num-
bers in gyrencephalic primates135-137 and are considered piv-
otal to the evolutionary increase of human cortex surface
size and complexity.138 The oRG population is largely
absent during mouse brain development.139 Therefore,
human cellular models provide a unique opportunity to
study this cell population. Even more compelling would be
to study these and other neural progenitors in the developing
human brain using a cell culture system that models the 3D
architecture of human forebrain neural progenitor zones and
the developing cortical mantle. A recently developed cell
culture technology, known as cerebral organoids, brain
organoids, or cortical spheroids, now enables this approach.
The general method involves growing hPSC aggregates in
suspension such that they differentiate into self-organizing
cerebral-like 3D neural structures.24,25 Depending upon the
specific protocol, the structures resemble diverse regions of
brain and recapitulate several key in vivo features of brain
organogenesis. Thus, they are attractive models for studies of
unique aspects of brain development, and allow modeling of
human brain disorders in 3D. A growing number of protocols
have been developed to differentiate organoids that partly reca-
pitulate specific CNS regions such as the hippocampus,140
midbrain,141,142 hypothalamus,29 cerebellum,143 thalamus,31
oligodendrocytes/white matter,144 anterior pituitary,145 and ret-
ina.146 Here we highlight recent advances in generating forebrain
cerebral organoids that contain cortical glutamatergic neurons
and cortical interneurons.
Although neurons in monolayer cultures can develop
functional synapses and form neuronal networks, traditional
2D cultures are still limited in their ability to recapitulate
human brain cytoarchitechture and to be maintained for
the extended time periods necessary for human neural
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development. Neurons in brain organoids arguably show
greater neuronal maturation than those from 2D monolayer-
derived neurons.28 The decreased maturation potential of 2D
cell cultures may reflect a lack of the complex extracellular
environment necessary to generate appropriate cell-cell con-
nections and extracellular matrix interactions. This short-
coming and the ability for prolonged (> 1.5 years) culturing
of organoids make 3D tissue-like structures a more promis-
ing model to achieve mature human brain-like networks.
The 3D culture models are not just more heterogeneous and
complex than 2D neural cultures, but also more physiologi-
cally relevant to structures of human brain in terms of the
spatial organization of tissues and electrophysiological prop-
erties of neural cells.147-152 Cerebral organoids generate a
laminar organization that partly recapitulates human cortical
development, such as defined multilayer progenitor zone
organization (VZ and inner/outer SVZ) and diverse neural
cell types with identities of potentially all six layers of
developing neocortex. Many studies have described the
appearance of astrocytes28,29,153 and less frequently oligo-
dendrocytes,154 in cortical organoids during later stages of
differentiation. More recently, human oligodendrocyte-
lineage containing brain organoids were developed to gen-
erate oligodendrocytes that are transcriptionally similar to
human fetal oligodendrocytes and mature both morphologi-
cally and electrophysiologically over time.144,154,155
Protocols for generating cerebral organoids from hPSCs
are evolving rapidly in this fast moving field. These proto-
cols often require two processes: the establishment of neural
identity and the recapitulation of 3D structural organization.
One approach for generating cerebral organoids is known as the
“intrinsic protocol” based on the self-organizing potential of
stem cells. As a result, each organoid is typically comprised of
diverse cell types found in forebrain, hindbrain, and retina.25,26
More recently, this self-organizing approach has been modified
to generate region-specific brain organoids. The method
depends on the specific temporal application of extrinsic signal-
ing molecules (reviewed in Reference 149) that pattern EBs and
neural progenitors to adopt the fate of the desired brain
region.27-29,31,32 For generating forebrain cortical organoids,
hPSCs are allowed to develop into EB-like aggregates, which
have three germ layer differentiation potential. Subsequent sus-
pension culture of EBs in a minimal medium, in the presence of
SMAD signaling inhibitors, inhibits mesoderm and endoderm
formation and instead promotes the formation of neural rosettes,
a polarized organization of neuroepithelial cells and the later
source of diverse neural progenitors. EBs are then embedded
in a Matrigel scaffold25,29,156 or cultured in medium with a
low concentration of Matrigel30,157,158 to support the self-
organization of the neuroepithelium and to induce the correct
polarity signals for the development of an apicobasally polar-
ized neuroepithelial bud. The neuroepithelium further develops
into structures that are remarkably similar to the VZ and SVZ
regions of the developing human brain. These include an
oSVZ region that contains oRG cells that are crucial for
human cortical expansion.6 The support by Matrigel in some
protocols seems to be critical for the building of in vitro brain
structures.29 Later agitation, such as those provided by spin-
ning bioreactors,29 or mechanically cutting the organoids30 to
remove the necrotic center promotes the development of much
larger and more uniform cortical organoids. The organoids
contain fluid-filled cavities that resemble brain ventricles,25
and generate neurons with identities of deep and superficial
layers of neocortex. A simplified approach for cortex-specific
organoid generation that does not require extracellular matrix
support and media agitation also yields cortical spheroids with
well-defined segregation of superficial and deep cortical
layers.28,31,32
Much of the initial effort was focused on cortical organoids,
emphasizing the development of glutamatergic cortical neurons.
Few interneurons are found in standard cerebral organoids/
cortical spheroids28,29 because the organoids are generated from
protocols that promote dorsal cell fates through inhibition of
WNT and SHH pathways and thus lack tissue resembling
the ventral ganglionic eminences. To rectify this problem,
ventralized organoids containing GABAergic interneurons have
been generated. Similar to the generation of GABA interneurons
in 2D culture, the EBs can be pattered to ventral forebrain
organoids/spheroids by combined activation of the SHH path-
way and WNT inhibition,26,27,32,159 or SHH pathway activation
alone.30 These ventral organoids develop ventricular zone (VZ)-
like structures expressing NKX2-1 and later generate
GABAergic interneuron subtypes. They also can be fused to
dorsalized glutamatergic organoids in vitro.27,32,159 The fused
forebrain assemblies demonstrate the migration of interneurons
from the ventralized (GE-like) organoid into the dorsalized
organoid and establishment of circuits with glutamatergic cells,
mirroring normal developmental processes observed in the fetal
forebrain.27,32,159
In terms of neuronal function, organoids can be grown for
more extended periods of time compared to 2D cultures, all-
owing for increased neuronal maturation. Initial studies showed
the presence of slow neuronal calcium waves and action poten-
tials induced by current injections.25,28,29 Both glutamatergic
and GABAergic synaptic transmission is present in cortical
organoids.29 Evoked action potential firing rates and excitatory
synaptic inputs increase substantially in fused forebrain
organoids that are comprised of glutamatergic and GABAergic
neurons in a more physiological ratio.27 Prolonged culture
(up to 20 months) of human cortical spheroids also promotes
astrocytic maturation.153 Recent studies showed that spontane-
ous neuronal network activity could be detected in 8-month-
old brain organoids through extracellular recordings with
high-density silicon microelectrodes.156 Loss of this activity in
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the presence of neurotransmitter receptor antagonists suggests
the presence of synaptic networks in the organoids. Thus, this
technology offers new opportunities to study both neuronal
dynamics in developing human brain-like structures and the
neural circuitry underlying disease mechanisms of epilepsy and
other neurological disorders.
5 | ASSAYS FOR MEASURING
HPSC-DERIVED NEURONAL
ACTIVITY AND DIFFERENTIATION
Various methods can be used to determine the function of
neurons generated from hPSCs. Traditional electrophysio-
logic techniques, such as patch-clamp recordings, provide
insight into intrinsic cellular and synaptic properties that
may lead to epilepsy.44,67 Such studies can be performed on
2D neuronal cultures, but they also can be applied to acute
slices or dissociated cells from organoid cultures. Moreover,
electrophysiological activity of hPSC-derived neurons
transplanted into the rodent brain may be assayed in ex vivo
brain slices.36,160 However, patch clamp techniques are labor
intensive, and typically only permit recording from individual
cells at a single time point during development. As an alterna-
tive, tissue culture plates with embedded multielectrode arrays
(MEAs) may be used to measure extracellular field potentials
of neuronal cultures.161-163 MEAs allow for longitudinal real-
time measurements of spontaneous activity from dozens of
neurons under normal culture conditions. This technique also
allows for repeated recordings from different cell types grown
under various experimental conditions in multiple-well format.
MEA recordings are often combined with drug application.
For example, one study used such recordings to identify a drug
that blocks hyperexcitability in ALS patient iPSC-derived
motor neurons.164
Another approach for assaying functional activity of iPSC-
derived neurons is to use optical Ca2+ imaging to detect tran-
sient increases of calcium concentration in active neurons. This
imaging is often accomplished by using either bulk loading of
chemical-based fluorescent calcium indicators,64 or by
expressing genetically encoded indicators of Ca2+ concentra-
tion such as GCaMP6.165-167 For example, in studying Timo-
thy syndrome caused by a mutation in the Cav1.2 calcium
channel, the investigators used the Fura-2 dye to show that the
phenotype of dendrite retraction is independent from calcium
flux through the channel.64 Calcium oscillations can be moni-
tored to show network formation through automated and non-
invasive imaging in 96- or 384-well plates.168-171 Calcium
imaging has been performed in either intact or dissociated
cerebral organoids to demonstrate that spontaneous surges of
intracellular calcium correspond to electrical activity.25,28,32 In
addition, in vivo two-photo calcium imaging systems can be
applied for longitudinally measuring neuronal network activi-
ties of grafted organoids in rodent brain.172
Although Ca2+ imaging is applied to multiple cells simulta-
neously, it typically lacks the temporal resolution to reliably
distinguish individual action potentials and does not reliably
measure local field potentials. In contrast, high-density silicon
microelectrodes have recently been developed to obtain scal-
able spatially oversampled neural recordings in live mamma-
lian brain. Each probe comprises up to 1000 electrode pads on
five shanks with 200 recording sites per shank.173 This
approach makes it possible to record large populations of sin-
gle unit activity from multiple brain structures in freely mov-
ing animals. Application of this technology to 8-month-old
human brain organoids enabled the detection of spontaneously
active neuronal networks.156
In addition to electrophysiologic and calcium imaging
studies, image-based techniques are available to study the
morphology of iPSC-derived neurons. Measuring neurite
outgrowth in culture is perhaps the most common pheno-
typic assay to study neuronal maturation in vitro.174 In addi-
tion to neurite length, the complexity of neurite branching,
number of extensions per cell, and number of neurites per
cell can be measured by image segmentation. Sholl analy-
sis175 is often used and provides the number of dendrite
intersections against the radial distance from the soma cen-
ter.176 Recent developments in automated live-cell imaging
systems allow for longitudinal and high-throughput pheno-
typic screens of neurite outgrowth of iPSC-derived neurons
in monolayer cultures.177-180 Assessing neuronal morpholog-
ical changes is helpful for understanding the mechanisms of
neurological disorders, as well as quantifying the effects of
potential drug treatments.181
Lastly, molecular characterization such as transcriptome
analysis offers a powerful strategy to provide valuable insight
into complex biological systems, including the CNS, using
molecular signatures. Conventional bulk transcriptome analy-
sis using RNA sequencing (bulk RNA-seq) provides the aver-
age transcriptional patterns for entire cell populations. In
contrast, single-cell RNA sequencing (scRNA-seq) enables
high-throughput (up to thousands of cells per experiment)
analysis of an entire transcriptome at a single-cell level.182-184
scRNA-seq often involves four major steps: isolating single
cells, capturing their transcripts, generating sequencing librar-
ies in which the transcripts are mapped to individual cells, and
analyzing and interpreting scRNA-seq data. Due to technical
noise (ie, low amount of starting material and high drop out
rate) and inherent biological variation, scRNA-seq often pro-
duces nosier and more variable data than bulk RNA-seq.185 In
bulk RNA-seq experiments, batch effects can be minimized by
preparing sequencing libraries from biological replicates in
parallel and then sequencing them simultaneously. However,
in scRNA-seq experiments, this is not feasible, as cells from
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different conditions are often captured and prepared indepen-
dently due to the lower throughput of this platform.186 Appro-
priate controls and a minimum of three biological replicates
per condition are recommended, and also functional validation
is an important step to assess the relevance of these data to the
biological context.186
Although plenty of improvements are in need, scRNA-seq
is best suited to efficiently reveal the complex cellular diversity
in brain organoids,187 track the trajectories of distinct cell line-
ages in development,27,32,156 and to understand organoid-to-
organoid variability.156,158 Camp and colleagues were the first
to directly compare cerebral organoids with human early fetal
neocortex using scRNA-seq based on the Fluidigm system
and found that in vivo cell lineages and gene expression pro-
grams were largely recapitulated in the organoid cortical
regions.187 A major limitation of this study was the low
throughput of scRNA-seq technology (less than 1000 cells per
experiment). Quadratto et al. substantially advanced the char-
acterization of self-patterned whole-brain organoids using a
higher throughput scRNA-seq microdroplet-based micro-
fluidics platform.156 Using this Drop-seq based method the
authors sequenced over 80 000 cells from 31 brain organoids
and found that neurons in multiple lineages progressively
matured over time at the transcriptome level. Notably, the
authors also reported significant organoid-to-organoid variabil-
ity related to bioreactor-based batch effects identified in the
scRNA-seq analysis,156 which was confirmed by a recent
study using a similar approach to generate self-patterned
multi-region brain organoids.158
6 | iPSC MODELS OF GENETIC
EPILEPSIES
iPSC models of genetic epilepsies include those in which epi-
lepsy is the defining feature/symptom, such as DS or
STXBP1-Related Epileptic Encephalopathy, and disorders in
which epilepsy is a variable feature associated with other
neurodevelopmental abnormalities, including TSC, Rett syn-
drome, Fragile X syndrome and Timothy syndrome. Many of
the recent studies of epilepsy-associated genetic diseases
have focused on those with an onset in infancy or early child-
hood given the relative ease of modeling defects in early neu-
ral development with hPSCs. Although an epileptic-like
phenotype is not as well-defined using in vitro models as it is
in animal models, in vitro models have been used to show
increased spontaneous action potential firing rates and
increased bursting and synchrony as correlates of epileptic-
like activity. Patient-derived iPSC models for many of these
diseases have also demonstrated altered neuronal morphology
including soma size, neurite outgrowth, synapse formation,
and dendritic spine length.50,188,189 2D iPSC models have
been particularly important for analyzing parameters such as
gene expression, cell morphology, neuronal excitability, and
synapse formation since 2D cultures are easy to manipulate
and readily available.190-192 Several reviews have summa-
rized the modeling of genetic epilepsies and other related
neurological disorders in monolayer neurons.71,193 However,
3D brain organoid modeling, with its more complex laminar
organization, cell diversity, and mature neural networks,
opens the door to new possibilities for modeling epilepsy
related disorders. Benefits and disadvantages of different
model systems for human brain disorders have been summa-
rized recently (summarized in Figure 1).148 In subsequent
sections of this review, we describe studies using 2D or 3D
hPSC-derived cultures to model the abovementioned genetic
epilepsies and related neurodevelopmental disorders with a
focus on human brain-specific phenotypes.
6.1 | Dravet syndrome
Dravet syndrome (DS) is a severe childhood epileptic enceph-
alopathy that typically presents in infancy with treatment-resis-
tant, prolonged seizures, and subsequent developmental delay
and intellectual disability.194 In over 80% of cases, the cause is
a de novo heterozygous mutation in the SCN1A gene, which
encodes the voltage-gated sodium channel (VGSC) Nav1.1,
leading to haploinsufficiency.195 Opening of VGSCs results in
an influx of sodium ions necessary for the firing of action
potentials, making haploinsufficiency of this sodium channel
seem unlikely to cause epilepsy. Prior heterozygous knockout
or human mutant SCN1A knock-in mouse models suggested
an answer to this apparent paradox with the finding of selec-
tive decreases in interneuron excitability predicted to cause
disinhibition and cortical hyperexcitability.196,197 However,
recent work with DS patient iPSCs and additional mouse stud-
ies support a more complex pathophysiology.
Several groups generated iPSCs from DS patients, dif-
ferentiated them into excitatory and inhibitory neurons and
used whole-cell patch-clamp recordings to examine neuro-
nal electrophysiology. One group unexpectedly showed
increased (rather than the expected decrease seen in mouse
interneurons) sodium current (INa) density and excitability
in both presumptive excitatory and inhibitory neurons
derived from two DS subjects compared to unrelated con-
trols.44 This result was supported by another study of one
DS patient that also found increased INa in excitatory neu-
rons.122 However, several other groups have reported
decreased INa in iPSC-derived interneurons with mutant
SCN1A-linked DS,45,157,198 and one of these studies used a
more advanced protocol to generate interneurons of a
medial ganglionic eminence-like origin and also showed
unchanged INa in excitatory neurons.
45 The variability in
results may be secondary to differences in the methods of
neuronal differentiation, neuronal subtypes, or the maturity
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of the neurons. Subsequent DS mouse model studies com-
plicated the picture further, showing a developmental tran-
sition where initially interneurons have decreased INa and
hypoexcitability, but then, due to unknown compensatory
mechanisms, the interneurons normalize and excitatory
neurons show increased INa
199,200 and excitability.200
Taken together, the DS human iPSC and mouse data sug-
gest that interneuron dysfunction initiates the epileptic
encephalopathy, but resultant abnormalities in excitatory
neurons may maintain the epileptic state.
6.2 | STXBP1-related epileptic
encephalopathy
STXBP1-related epileptic encephalopathy is a severe epilepsy
that typically begins in early infancy and results from STXBP1
haploinsufficiency.201 STXBP1 is a protein that is critical for
effective presynaptic vesicle release. Several groups have found
abnormal phenotypes in both patient-derived iPSC and
genetically modified conditional hESC models of STXBP1-
Related Epileptic Encephalopathy. The abnormalities include
decreased SYNTAXIN1 expression/altered localization,
decreased neurite outgrowth and reduced neurotransmitter
release associated with heterozygous STXBP1 LOF.50,189
In homozygous STXBP1 null hESC lines, severe neu-
rodegeneration also occurs.189
6.3 | Tuberous sclerosis complex
TSC is a multisystem disorder that most prominently affects
the skin, brain, lungs, kidneys, and heart. The disorder is cau-
sed by autosomal dominant de novo or inherited mutations in
either the TSC1 or the TSC2 gene that encodes hamartin or
tuberin, respectively.202 The mutations are LOF and they lead
to variable hamartomas in these tissues that reflect abnormal
cell growth. The variability is thought to be due to the require-
ment for “second hit” mutations leading to loss of heterozy-
gosity and subsequent hamartomas. TSC1 and TSC2 form part
FIGURE 1 Overview of schema for studying genetic neurodevelopmental disorders using iPSC-derived 2D and 3D models. Patient somatic
cells, such as peripheral blood mononuclear cells (PBMCs) or fibroblasts, are reprogrammed into iPSCs and then may be differentiated into 2D
neuronal cultures or 3D brain organoids. iPSC colonies express pluripotency-associated genes such as octamer-binding transcription factor 3/4
(OCT3/4; green) and stage-specific embryonic antigent-4 (SSEA4; red). In hPSC-derived 2D neural cultures generated from a dual-smad
differentiation protocol18, neural VZ-like rosette structures (left) and cortical-like excitatory neurons (right) that express mictrotubule-associated
protein 2AB (MAP2AB; green), and vesicular glutamate transporter-1 (VGLUT1; magenta) form after ~3 or 6 weeks of differentiation, respectively.
In 3D cortical organoid culture generated using a published protocol (by Reference29), apicobasally polarized neuroepithelial buds (left) appear
after 10 days of differentiation. Defined VZ-like structures with N-cadherin (NCAD; green) at the apical surface and neural progenitor cells
immunolabeled for nestin (red) are seen at 34 days of differentiation (right). Although each system has unique advantages for modeling human brain
disorders, hPSC-derived in vitro models provide unprecedented platforms for elucidating disease mechanism, biomarker identification, drug
screening and toxicity studies, and eventually designing personalized treatments. Scale bar: 100 μm except for the image with iPSC cells
immunolabeled with OCT3/4 and SSEA4 (10 μm)
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of a heterotrimeric complex that represses the mechanistic tar-
get of rapamycin (mTOR) pathway, and LOF results in mTOR
hyperactivity that causes aberrant cell growth.203 In the brain,
the main abnormal growths are cortical tubers, a type of focal
cortical dysplasia (FCD), that most commonly present as sei-
zures at any point in life from infancy to adulthood. Develop-
mental delay, psychiatric disturbances, intellectual disability,
and autism spectrum disorder are also often seen. Less fre-
quently, subependymal giant cell astrocytomas arise in the
brain and may lead to hydrocephalus.
Human PSC models of TSC have recently been devel-
oped to complement previous animal studies (see Reference
204). Costa and colleagues188 generated heterozygous and
homozygous TSC2 knockout hESC lines via genome editing
and found disease-relevant phenotypes, predominantly in
homozygous lines. The phenotypes included increased neu-
ral progenitor proliferation, delayed neuronal differentiation,
enhanced generation of astrocytes, and increased neuronal
soma size and dendritic complexity. In terms of functional
effects, TSC2 knockout hESC-derived (mainly excitatory) neu-
rons showed reduced evoked action potential firing and
decreased spontaneous and miniature excitatory postsynaptic
currents, findings that do not seem to explain the common epi-
lepsy phenotypes in patients, although the function of cortical
inhibitory-like neurons was not specifically assessed. The mor-
phological and functional phenotypes were associated with
increases in markers of mTOR pathway hyperactivity, again to
a much greater degree in homozygous TSC2 null cells, and
they were reversed by the mTOR inhibitor rapamycin. Multi-
ple groups subsequently found more subtle but similar pheno-
types in haploinsufficient TSC1 or TSC2 patient iPSC-derived
forebrain neurons or purkinje cells.52-55
Recently, Blair and colleagues combined brain organoid
and CRISPR gene editing methods to model TSC in 3D cul-
tures.51 They generated hESC lines with either constitutive
heterozygous or homozygous null TSC1 or TSC2 alleles, or
lines with one null and one conditional TSC2 allele, the latter
to model a second hit during various stages of brain organoid
development after the viral introduction of Cre to delete the
second TSC2 allele, while also activating a Cre reporter placed
in a safe harbor locus. Similar to previous 2D findings in gene
edited TSC lines,188 phenotypes were present in cortical spher-
oids generated from homozygous null lines and largely absent
in those derived from heterozygous lines. The changes
included expression of markers indicating increased mTOR
pathway activation, decreased neuronal and increased astro-
cytic differentiation, and enlarged, dysmorphic neurons and
glia resembling TSC patient cortical tubers. Remarkably, focal
Cre delivery to delete the conditional second allele in brain
organoids from lines with constitutive haploinsufficiency led
to the focal generation of tuber- or FCD-like abnormalities in
the organoids. The authors replicated the findings by similarly
inducing a focal knockout of a conditional allele generated
from TSC patient iPSC-derived spheroids as a second hit.
They also showed that early rapamycin treatment of the brain
organoids prevented development of the abnormal phenotypes.
Given the lack of findings in heterozygous TSC loss-of-
function organoids, this elegant work provides strong support
for the two-hit hypothesis of TSC pathophysiology.
6.4 | Rett syndrome
Rett syndrome (RTT) is arguably the most studied epileptic
disorder using iPSCs. RTT is an X-linked neurodevelopmental
disorder caused primarily by mutations in MECP2, which
encodes a multifunctional epigenetic regulator.205 Strikingly,
50%-90% of RTT patients have seizures.206 iPSC models of
RTT patients from several groups showed that RTT mutant
neurons display a decrease in neuronal soma size, neurite out-
growth, synapse formation, and spontaneous activity, com-
pared to wild-type MECP2-expressing neurons derived from
isogenic RTT patient iPSC lines.57,59 Marchetto and col-
leagues also demonstrated rescue of the MECP2 mutation
associated phenotypes via insulin-like growth factor-1 (IGF1)
treatment.59 Interestingly, mutant RTT astrocytes derived from
RTT patients have adverse effects on the morphology and
function of wild-type iPSC-derived neurons.23 This finding
demonstrates the critical roles played by glia in RTT pathology
and the need to consider astrocytic contributions to epi-
leptogenesis. Although postnatal functions of MECP2 have
been extensively investigated, the role of MECP2 in early brain
development remains poorly understood. Mellios and col-
leagues used RTT patient-derived iPSCs and MECP2 knock-
down by shRNA to identify novel MECP2-targeted miRNAs
during neuronal development. They also used MECP2-deficient
and patient-derived monolayer culture and cerebral organoids to
identify defects in neurogenesis, neuronal differentiation and
migration.60 They found a novel signaling pathway mediated
by MECP2-targeted miRNAs that might influence neurogenesis
and early brain development.60 This study also suggests that
early disruptions in brain development could result in increased
susceptibility to subtle postnatal deleterious effects on brain
maturation and plasticity, thus contributing to the full pathogen-
esis of neurodevelopmental disorders.
6.5 | Miller-Dieker syndrome
Miller-Dieker syndrome (MDS) is a severe congenital form of
lissencephaly. It is caused by a heterozygous deletion of chro-
mosome 17p13.3, which leads to a severe malformation of cor-
tical development.207,208 Affected children suffer from feeding
difficulties, severe intellectual disability, developmental delay,
and seizures. Past studies of this disease largely relied on mouse
models, which have the obvious disadvantage of being naturally
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lissencephalic. Although human brain organoids have not yet
recapitulated gyrification, they contain most relevant cell types
and structures likely to be involved in disease development.
Patient iPSC-derived human brain organoids were recently used
in two studies to investigate how MDS affects human progeni-
tor subtypes (such as oRG cells) that control neuronal output
and influence brain topology. One study showed a neuronal
migration defect and severe apoptosis of the founder neur-
oepithelial stem cells in the VZ-like region. The authors also
found a migration defect in the oRG cells, a cell type that is
largely absent from lissencephalic rodents but critical for human
neocortical expansion.68 Similarly, Iefremova and colleagues
used patient-specific forebrain organoids to investigate patho-
logical changes associated with MDS. They found that patient-
derived organoids are reduced in size, a change accompanied
by a switch from symmetric to asymmetric cell division of VZ
radial glial cells.209 In addition, they identified non-cell-
autonomous defects in the WNT signaling pathway. These
important studies provide insight into the cellular pathogenesis
of lissencephaly and demonstrate the utility of using brain
organoids to model human-specific phenotypes.
6.6 | PTEN macrocephaly
The phosphatase and tensin homolog (PTEN)-protein
kinase B (PKB)/AKT cascade regulates human cortical
development,210,211 and PTEN heterozygous loss-of-function
mutations have been found in patients with macrocephaly.212,213
In the human cerebral organoid system, deletion of the PTEN
gene by CRISPR/Cas9-mediated genome editing increases AKT
activity in human neural progenitors, promotes cell cycle re-entry,
and transiently delays neuronal differentiation.69 These alterations
result in a pronounced expansion of the radial glia and intermedi-
ate progenitor cells. In this study, both mouse and human brain
organoids were used to model macrocephaly and showed that the
lack of PTEN led to a significant increase in size (recapitulating
macrocephaly), but only knockout human organoids displayed
substantially increased surface folding. The phenotypic dif-
ferences might reflect inherent species differences in signal-
ing regulation, cellular response, or brain cytoarchitecture.
The use of human brain organoids thus can produce human-
specific phenotypes and provide unique insights into under-
lying disease mechanisms.
7 | ZIKV INFECTION
Although not a genetic cause of epilepsy, congenital ZIKV
virus infection is known to cause microcephaly and severe
brain abnormalities in infants,214-216 and infected subjects
also have a high risk of epilepsy.217 Recent studies using
human brain organoids to model ZIKV infection have dem-
onstrated that it induces the death of neural progenitor cells
and impairs organoid formation, providing certain mechanis-
tic insights into disease pathogenesis.29,218,219 However,
none of these studies recapitulated the key developmental
features of the human cortex such as surface area and fold-
ing. In contrast, genetically modified PTEN mutant brain
organoids show increased surface area and folding, and were
used to model the destructive effect of ZIKV infection on
these key features of the human cortex in vitro.69 In this
study, ZIKV infection led to the widespread initiation of
apoptosis at the onset of surface folding and later severely
impaired organoid growth both in size and surface folding.
Furthermore, recent work has exploited brain organoid tech-
nology in developing drugs or screening therapeutic com-
pounds that can mitigate the destructive actions of ZIKV
infection on fetal brain.30,220,221 Importantly, these findings
further illustrate the strength of the human brain organoid
system in modeling complex structural malformations of the
developing human brain, and in recapitulating human neural
progenitor-specific pathology.
8 | LIMITATIONS, CHALLENGES,
AND FUTURE DIRECTIONS
While the use of hPSC-based models offers many advantages,
modeling epilepsy and other neurological disorders with
hPSCs also presents several challenges. One issue, mentioned
earlier, concerns the variability of iPSC lines within and
between subjects. Using isogenic controls generated by gene
editing along with multiple lines per condition partially allevi-
ates this problem. Another critical question is how closely
hPSC-derived neurons reflect those that are affected in human
epilepsies. Because hPSC-derived neurons are differentiated
in vitro for only weeks to months, they typically represent an
earlier developmental stage compared to in vivo development.
If the onset of seizures is associated with a gene expressed at a
later stage of brain development, hPSC derived neurons may
not reflect the critical gene alteration in patient brains. Sec-
ondly, although transcriptional profiles of 2D hPSC monolayer
neuronal cultures show remarkable preservation of in vivo
neurodevelopmental signatures from embryonic to early fetal
corticogenesis, these neurons do not mature beyond fetal
stages in vitro.222 Different compounds or conditions have
been used to accelerate the rate of maturation, including
gamma secretase inhibitors (DAPT and compound E) that
block notch signaling, neurotrophic factors, and co-culture
with either human or rodent astrocytes.223 The lack of matura-
tion may also be alleviated partially by using improved culture
media, such as BrainPhys,224 and with the development of
mature neuronal reporters that label purely mature neurons for
electrophysiological study. Moreover, these approaches may
be combined with NGN2-directed differentiation, yielding a
more homogeneous population of mature neurons.121
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A major limitation of organoid models is the relative
immaturity of neuronal circuitry compared to their in vivo
counterpart. Transcriptional profiles of cortical organoids
that are cultured up to 100 days in vitro recapitulate those of
about 16-24 week postconception human brain.28,187 More
recent studies suggest that the prolonged culture of human
brain organoids leads to further maturation beyond early
developmental stages.156,225 One study found spontaneous
action potentials and defined synaptic junctions in 8-month
old brain organoids, but not in younger ones, suggesting that
long-term culturing can promote functional neuronal con-
nectivity.156 Human cortical circuits require the assembly of
both glutamatergic neurons that are generated in the dorsal
forebrain and GABAergic interneurons that are produced in
the ventral forebrain. In the dorsal-ventral fused organoids
described earlier, interneurons that migrate into cortical
spheroids fired action potentials at twice the rate of cells in
unfused ventral spheroids.27 This finding suggests that pre-
patterned organoids can be fused to promote the formation
of functional synapses and neuronal maturation. Grafting of
cerebral organoids into rodent brain in vivo also yielded pro-
gressive differentiation and maturation.172 Another recent
approach used to enhance maturation and decrease cell death
within brain organoids involves culturing them at a liquid-
air interface, which improves neuronal survival and mor-
phology with extensive axon outgrowth following long-term
in vitro culture.225 However, many human cortical circuits
develop postnatally, and may take years to mature in vivo.
In particular, the development of parvalbumin fast-spiking
interneurons in 2D or 3D hPSC-derived neuronal cultures
has been challenging. Thus, significant challenges of circuit
maturation in brain organoids remain.
Another obstacle to the application of hPSCs for disease
modeling involves their limited ability to reproducibly reca-
pitulate the diversity of neural cell types and regional speci-
ficity found in the human brain. There are numerous
neuronal subtypes in human brain, organized by brain
region, layer, connectivity, neurotransmitter content, and
transcriptional profiles. These various neuronal subtypes
make diverse contributions to the epileptic phenotype. In
addition, although neurons in 3D brain organoids have more
complex anatomic connectivity and neuronal networks than
2D monolayer neurons do, many nonneuronal cell types
found in the brain such as oligodendrocytes, meningeal cells,
microglia and brain microvascular endothelial cells remain
challenging to incorporate into brain organoid cultures
in vitro.26,28,226 This is largely due to the lack of surrounding
supportive tissues and endogenous developmental and pat-
terning cues in the organoids. The “intrinsic” organoids
mainly depend on the ability of stem cells to spontaneously
acquire neural identity and to self-organize into brain-like
structures. This promotes the generation of somewhat
diverse brain-like regions and cell populations.26 Although
such diversity is appealing, it often leads to inconsistent out-
come and batch effects that may conceal critical phenotypes.
Thus, reproducibility and consistency are substantial chal-
lenges in these self-organizing brain organoid protocols182
On the other hand, recent “extrinsic” protocols create
brain-region specific organoids whereby patterning is
restricted by externally added morphogens, and these have
shown promise in improving reproducibility. For example,
the dorsal forebrain organoids that were recently developed
by Velasco et al., reliably generate a rich diversity of cell
types similar to those in the human cerebral cortex and show
consistent reproducibility in the cell types produced in these
region-specific organoids.158 Although these methods
restrict the ability to generate complex brain structures com-
pared to the “intrinsic” protocols, this shortcoming can be
partially overcome by assembling different types of
organoid-derived structures in vitro, generating so-called
“assembloids.” For example, fusion of human cortical
organoids and human subpallial organoids creates functional
human forebrain structures that contain both glutamatergic
excitatory neurons and GABAergic inhibitory interneu-
rons.27,32,159 A similar assembloid approach has been used
to reconstruct thalamo-cortical circuitry from hPSCs.31
These approaches are especially significant for investigating
epileptic-like phenotypes of interconnections between excit-
atory and inhibitory neurons, or those involving cortical-
thalamic/thalamocortical networks. Tissue engineering and
biomaterials will be also important for adding structural fea-
tures that are normally present in human brain into
organoids. For example, one group has combined hPSC-
derived neural progenitor cells, endothelial cells, mesenchy-
mal stem cells, and microglia/macrophage precursors on
chemically defined polyethylene glycol hydrogels to enable
these cells to develop into 3D neural structures and to model
cellular interactions within the developing brain.227
Although still preliminary, this work supports the feasibility
of integrating nonneural cells or tissues into brain organoids
to investigate more complicated cellular interactions in the
developing brain. This approach is especially important for
investigations of neurodevelopmental disorders, including
epilepsies, that require these cellular interactions during
developmental processes such as neuronal migration, syn-
aptogenesis, maturation, and network homeostasis.
With increasing knowledge of human cortical development
and progress in the development of differentiation protocols,
there have been a growing number of methods that researchers
can use to interrogate cellular properties of interest in brain
organoids. Although there is not yet a standard practice in this
field, the sampling of multiple organoids per experiment at
multiple developmental time points, ideally also with
organoids derived from multiple iPSC lines, is optimal to
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mitigate outlier effects. It will be also important for the disease
features to be replicated by multiple laboratories in order to
support their true relevance. While forming a “standard” proto-
col is unrealistic, detailed reporting of differentiation methods
in published studies is an imperative practice (see Table 1 for
examples of the numbers of organoids and/or cell lines ana-
lyzed in various selected studies).
9 | CONCLUSIONS
The need to create alternative models of human epilepsy has
been highlighted by the difficulties/failures to translate find-
ings from animal models to clinical therapies. Although
there are still many challenges ahead, hPSC technology pro-
vides the unprecedented ability to model genetic epilepsies
by growing many renewable human cells in a dish and dif-
ferentiating them into disease-relevant neural cell types. In
particular, these models are well suited to investigate disease
mechanisms and for drug screening to discover new preci-
sion therapies to treat many severe genetic epilepsies and
related disorders. The approaches are facilitated by the rela-
tive ease of differentiating hPSCs to brain tissues that par-
tially recapitulate early human neurodevelopment in vitro. A
variety of hPSC-based models have already provided insight
into mechanisms for several of the genetic epilepsies.
Advances in the development of hPSC models will arise
from improvements in methods to derive specific neuronal
subtypes and neural circuitry in 2D and 3D cultures. Pro-
gress in the development of efficient and reliable genome
editing methods for hPSC lines will no doubt play a role in
these advances. Lastly, improved functional assessment of
neural activity and exciting higher throughput drug screen-
ing capabilities are on the horizon. Given the rapid advances
already realized, hPSC-derived models hold strong promise
for providing a better understanding of human brain devel-
opment, disease mechanisms, and new epilepsy therapies by
bridging the gap between model systems and patients.
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